Richard young 2023

Richard Young

Managing Director and Principal Toxicologist

UKRT/ERT

Richard has >20 years’ experience in desk-based toxicology at bibra. He has an MSc in Applied Toxicology and is a RSB/BTS and European Registered Toxicologist (ERT). His skills include expert analysis of human health data. This can involve the pragmatic application of risk assessment methodology to mammalian toxicity data sets in order to derive robust conclusions on toxicological acceptability and health risks to exposed populations. In 2018, Richard became the Managing Director of bibra.

Richard has worked for clients from the food and beverage, food contact materials, consumer goods, agrochemical, biocidal, industrial chemical, pharmaceutical, electronic cigarette and cannabinoid sectors. For the past 15 years, he has been heavily involved in assisting companies comply with their REACH registration obligations, including supporting registrants respond to ECHA Evaluation decisions. Richard has played a key role in assisting e-cigarette and e-liquid manufacturers and importers with the toxicological assessments of their products, notably with their EU TPD and US FDA PMTA compliance obligations. Most recently he has been involved in the toxicological assessment of cannabinoids (notably CBD and THC) for a number of clients from a range of sectors (e.g. food, consumer products and pharmaceuticals).

In his spare time Richard can be found playing padel tennis and 5-a-side football (when his knees can cope), and running around and entertaining his two children.

Richard's case studies and blog posts

CAATs out the bag: Unexpected Animal Use Figures Under REACH Testing

Blog articles

The European Union’s Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation, which came into force in 2008, emphasised that “before (proposing) additional animal testing, use of all other options should be considered. It is important to emphasise that testing on vertebrate animals must only be conducted or proposed as a last resort”.

Health risk assessments relating to the excipient components of the Voke® formulation

Case study

A novel nicotine replacement device was designed to deliver a pressurised nicotine formulation via a breath operated valve in a cigarette sized medical device. Kind Consumer received a Marketing Authorisation for its lead product, Voke®, in September 2014.

The identification of oral and inhalation Health Criteria Values (HCVs)

Case study

Health Criteria Values (HCVs) are expressed in different ways, using the terminology specific to the authority that is recommending them. Oral values represent a regular ingested dose that is expected to be without appreciable risk to the consumer over a lifetime.

Want to read more case studies and blog posts that Richard has been involved in? Click below to read more.

Contact us